ZA200208272B - Treatment of fibromyalgia and chronic fatigue syndrome. - Google Patents

Treatment of fibromyalgia and chronic fatigue syndrome.

Info

Publication number
ZA200208272B
ZA200208272B ZA200208272A ZA200208272A ZA200208272B ZA 200208272 B ZA200208272 B ZA 200208272B ZA 200208272 A ZA200208272 A ZA 200208272A ZA 200208272 A ZA200208272 A ZA 200208272A ZA 200208272 B ZA200208272 B ZA 200208272B
Authority
ZA
South Africa
Prior art keywords
fibromyalgia
treatment
chronic fatigue
fatigue syndrome
syndrome
Prior art date
Application number
ZA200208272A
Other languages
English (en)
Inventor
David W Robertson
Robert C Marshall
Robert B Mccall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA200208272B publication Critical patent/ZA200208272B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA200208272A 2000-04-21 2002-10-14 Treatment of fibromyalgia and chronic fatigue syndrome. ZA200208272B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19896000P 2000-04-21 2000-04-21

Publications (1)

Publication Number Publication Date
ZA200208272B true ZA200208272B (en) 2004-01-26

Family

ID=22735613

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208272A ZA200208272B (en) 2000-04-21 2002-10-14 Treatment of fibromyalgia and chronic fatigue syndrome.

Country Status (12)

Country Link
EP (1) EP1280530A1 (zh)
JP (1) JP2004502651A (zh)
KR (1) KR20020089510A (zh)
CN (1) CN1418099A (zh)
AU (2) AU2001255223B2 (zh)
BR (1) BR0110188A (zh)
CA (1) CA2404704A1 (zh)
HK (1) HK1054190A1 (zh)
MX (1) MXPA02010410A (zh)
NZ (1) NZ522115A (zh)
WO (1) WO2001087308A1 (zh)
ZA (1) ZA200208272B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US20220313682A1 (en) * 2019-08-07 2022-10-06 Aclipse One Inc. Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073555A (en) * 1988-04-04 1991-12-17 George D. McAdory Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IT1304904B1 (it) * 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
WO2001081343A2 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Also Published As

Publication number Publication date
NZ522115A (en) 2004-07-30
AU5522301A (en) 2001-11-26
AU2001255223B2 (en) 2004-10-21
MXPA02010410A (es) 2003-04-25
KR20020089510A (ko) 2002-11-29
WO2001087308B1 (en) 2002-05-16
JP2004502651A (ja) 2004-01-29
BR0110188A (pt) 2003-03-05
HK1054190A1 (zh) 2003-11-21
WO2001087308A1 (en) 2001-11-22
EP1280530A1 (en) 2003-02-05
CA2404704A1 (en) 2001-11-22
CN1418099A (zh) 2003-05-14

Similar Documents

Publication Publication Date Title
AU5311401A (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
MXPA03009562A (es) METODO PARA TRATAR EL SiNDROME X CON POLIAMINAS ALIFATICAS.
GB0129437D0 (en) Server and units
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
EP1575582A4 (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME
ZA200201832B (en) Cryogenic processing methods and apparatus.
AU2001292553A1 (en) Chronic illness treatment system and method
ZA200208272B (en) Treatment of fibromyalgia and chronic fatigue syndrome.
AU3895300A (en) Treatment of chronic fatigue syndrome
WO2005009337A3 (en) Treating severe acute respiratory syndrome
AU2002225881A1 (en) Treatment of chronic fatigue syndrome and fibromyalgia syndrome
EP1450831A4 (en) PROCESS FOR TREATMENT IN SITU IN THE LUNGS OF MAMMALS
AU2003230552A8 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
DE50210561D1 (de) Sitz- und/oder liegemöbel
ZA200209632B (en) Methods for prevention of ulcers and improving physiological performance.
SI1274430T1 (sl) Kabergolin za zdravljenje fibromialgije in sindroma kronicne utrujenosti
AU2001271264A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
GB0102609D0 (en) Improvements in fitted kitchens and the like
AU3663601A (en) Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis
SI1107744T1 (en) Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
ZA200301030B (en) Treatment of the insulin resistance syndrome.